Cancer Prevention and Control CIRB Meeting Agenda

March 28, 2024

I. Initial Review

**EA6232**, A Phase II Double-Blind Trial of Sulforaphane for Therapeutic Prevention of Melanoma in Patients with Multiple Atypical Nevi and a Prior History of Melanoma (Version Date 02/13/24)

II. Amendment

**EA8184**, A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers (Version Date 02/09/24)

III. Amendment

**WF-2201**, Hypofractionated Radiotherapy vs Single Fraction Radiosurgery for Brain Metastasis Patients on Immunotherapy (HYPOGRYPHE) (Version Date 01/19/24)

IV. Amendment

**URCC-21038**, Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-L1/anti-PD-L1 Immunotherapy in a Community Oncology Setting (Version Date 03/04/24)
V. Continuing Review

**MDA20-02-01**, Time Restricted Eating And Metformin (TEAM) in Invasive Breast Cancer (IBC) or Ductal Carcinoma in Situ (DCIS). A randomized, Phase IIb, Window of Opportunity Presurgical Trial. (Version Date 11/23/23)

VI. Continuing Review

**NRG-CC008**, A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROck] (Version Date 07/29/22)

VII. Continuing Review

**NWU20-02-01**, Surgical Window of Opportunity Study of Megestrol Acetate Compared with Megestrol Acetate and Metformin for Endometrial Intraepithelial Neoplasia (Version Date 12/11/23)

VIII. Continuing Review

**NWU20-02-02**, A Randomized and Placebo-Controlled Phase II Trial Targeting Dominant-Negative Missense Mutant P53 By Atorvastatin for Reducing the Risk of Longstanding Ulcerative Colitis-Associated Cancer (Version Date 12/21/23)
IX. Continuing Review

UWI20-00-01, A Phase II Trial of the Immunogenicity of a DNA Plasmid Based Vaccine (STEMVAC) Encoding Th1 Selective Epitopes from Five Antigens Associated With Breast Cancer Stem Cells (MDM2, YB1, SOX2, CDH3, CD105) in Participants with Triple Negative Breast Cancer (Version Date 01/16/24)